💙 Celebrating 100 years of Ambassador Theodore R. Britton Jr. — a Marine, diplomat, and lifelong advocate for Peace through Understanding. A century of courage, compassion, and global connection.

#PTPI #PeaceThroughUnderstanding #Leadership #Legacy

🌍 Quiet progress, real impact.
Across the PTPI network — from Estonia to Poland to Delaware — people are proving that Peace Through Understanding is action, not words. 💙

#PTPI #PeaceThroughUnderstanding #GlobalCommunity

PT reúne Executiva estadual, cobra fidelidade partidária e reivindica vaga de vice-governador Durante reunião em Teresina, novo diretório estadual do PT-PI firma compromisso por unidade e mira maior protagonismo nas eleições de 2026.

pensarpiaui.com/noticias/pt-...
#PT #ptpi #políticapiauí #eleicoes2026 #fidelidadepartidária #vicegovernador #executivaestadual #articulaçãopolítica #BrasilHoje #noticiasdodia #pensarpiaui

🍽️🌍 Greater Kansas City PTPI Council
Sponsors, Officers, & families came together for a Food Fair - 26 Sept — sharing flavors of many countries in one evening. A reminder of culture, community, Peace through Understanding. ✨

#PTPI #PeaceThroughUnderstanding #KansasCity #CulturalExchange #FoodFair

🌍✨ 20 September — World Cleanup Day

Every piece of litter removed is a step toward a cleaner, healthier planet. 🌱

👐 Small actions add up. Big impact starts local.

#PTPI #WorldCleanupDay #PeaceThroughUnderstanding #CommunityImpact #Sustainability #PandemicOfFriendship

Petros Pharmaceuticals Makes Bold Move to Save Nasdaq Listing: Strategic Subsidiary Split Transforms Balance Sheet Key subsidiary deconsolidation set to boost stockholder equity and reduce debt as Petros fights Nasdaq delisting. See how this strategic move reshapes company future.

#PTPI Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position

www.stocktitan.net/news/PTPI/petros-pharmac...

PT-PI realiza Encontro Estadual de Lideranças em Teresina O governador Rafael Fonteles, o ministro Wellington Dias e o presidente nacional do PT, senador Humberto Costa, irão participar do evento

PT-PI realiza Encontro Estadual de Lideranças em Teresina

pensarpiaui.com/noticias/pt-...
#PTPI #ptpi #FormaçãoPolítica #formaçaopolitica #LiderançasPT #EncontroEstadual #encontroestadual
#pensarpiaui

Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal Petros Pharmaceuticals to appeal NASDAQ delisting decision while holding $10M cash. Trading moves to OTC Markets on May 22. Get latest updates.

#PTPI Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets

www.stocktitan.net/news/PTPI/petros-pharmac...

Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer Petros Pharmaceuticals (NASDAQ:PTPI) has partnered with Innolitics to develop a first-in-industry SaaS platform for OTC drug development. With over $10 million in cash and reduced burn rate compared to Q4 2024, Petros is well-positioned to fund this technology platform. The system, designed within FDA's ACNU guidelines, aims to facilitate prescription-to-OTC transitions and includes features like patient self-selection tools, EHR integration, and retail pharmacy integration. Innolitics, having developed software for over 70 medical devices, will integrate AI, cybersecurity, and cloud-based components. The platform targets the self-care market, valued at $38 billion with 5.6% CAGR over 10 years, and could potentially support OTC switches for conditions like erectile dysfunction, high cholesterol, migraine, anxiety, and UTIs.

#PTPI Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer

www.stocktitan.net/news/PTPI/petros-pharmac...

Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform Petros Pharmaceuticals (NASDAQ:PTPI) has enhanced its AI platform with key improvements to support its SaaS-based technology for Rx-to-OTC drug switches. The upgrades include Deep Fake detection, improved facial and ID recognition, and enhanced image auto capture features.The company's SaaS and Software as a Medical Device (SaMD) solutions aim to facilitate the transition of prescription drugs to over-the-counter status, aligning with President Trump's Executive Order for greater Rx-to-OTC switch efficiency. Petros is developing this technology in accordance with FDA guidance and targeting the self-care market, valued at over $38 billion with an expected 5.6% annual growth rate over the next decade.

#PTPI Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform

www.stocktitan.net/news/PTPI/petros-pharmac...

Trump Healthcare Initiative Drives Petros Pharma's $38B AI Platform Innovation for OTC Drug Approvals Revolutionary AI-powered platform facilitates prescription to OTC drug transitions, targeting $38B self-care market. Aligns with Trump's healthcare initiative. See platform details.

#PTPI Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches

www.stocktitan.net/news/PTPI/petros-pharmac...

Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms Company's AI and Big Data technology positioned to drive strong industry collaborationCompany also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on

#PTPI Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms

www.stocktitan.net/news/PTPI/petros-proprie...

Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications Petros Pharmaceuticals (NASDAQ:PTPI) has announced a strategic partnership with a leading Big Data and analytics provider to enhance its AI-driven platform for Rx-to-OTC drug switches. The collaboration aims to integrate an automated credentialing solution to improve identity verification systems.The partnership will incorporate an advanced document capture and authentication system that uses a patented global ID library to verify patient identity and eligibility. This technology will analyze ID cards through computer or mobile devices, ensuring secure authentication for medication access.The Company is developing a proprietary technology-assisted platform as a Software-as-a-Medical Device (SaMD) concept, following FDA's guidance on Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU). This initiative targets the self-care market, currently valued at over $38 billion with an expected 5.6% annual growth rate over the next decade.

#PTPI Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications

www.stocktitan.net/news/PTPI/petros-pharmac...

Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study Petros Pharmaceuticals (NASDAQ:PTPI) has announced positive results from its expanded Application Comprehension study, testing its proprietary technology for Rx-to-OTC drug switches. The 400-patient study evaluated 31 objectives, successfully achieving 4 of 5 most critical objectives, all 9 second-tier critical objectives, and all 17 important objectives with an 84% lower bound threshold.The technology, enhanced with AI and big data integration, is being developed as a Software as a Medical Device (SaMD) platform. This aligns with the FDA's recently adopted 'Nonprescription Drug Product with an Additional Condition for Nonprescription Use' (ACNU) rules for Rx-to-OTC switches.The company aims to position itself as a key player in the self-care market, currently valued at over $38 billion with an expected 5.6% compound annual growth rate over the next decade. The platform could potentially facilitate pharmaceutical companies in pursuing Rx-to-OTC switches, extending access and commercial viability of their products.

#PTPI Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

www.stocktitan.net/news/PTPI/petros-pharmac...

Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing Deal - Strategic Move or Dilution Risk? Petros Pharmaceuticals raises $9.6M through 40M share offering with warrants at $0.24 per unit. Proceeds targeted for working capital and corporate growth.

#PTPI Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

www.stocktitan.net/news/PTPI/petros-pharmac...

Breaking News: ( NASDAQ: #PTPI ) Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

Petros Pharmaceuticals Unveils AI-Powered Platform for Revolutionary OTC Drug Transitions Petros launches proprietary AI and quantum computing platform targeting $38B self-care market, aligning with FDA's new ACNU rule for Rx-to-OTC drug transitions.

#PTPI Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

www.stocktitan.net/news/PTPI/petros-pharmac...

Petros Pharmaceuticals Unveils AI-Powered Platform for Revolutionary Rx-to-OTC Drug Transitions Discover how Petros Pharmaceuticals is transforming medication access through AI and quantum computing, developing innovative solutions for Rx-to-OTC transitions in healthcare.

#PTPI Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

www.stocktitan.net/news/PTPI/petros-pharmac...

JUST IN: ( NASDAQ: #PTPI ) Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

#StockMarket #News

Petros Pharmaceuticals Pivots to $38B Self-Care Market with AI-Powered Rx-to-OTC Platform Petros unveils strategic transformation with proprietary AI technology platform targeting the growing $38B self-care market, exploring quantum computing partnerships for drug switches.

#PTPI Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

www.stocktitan.net/news/PTPI/proprietary-te...